BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20522982)

  • 1. Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration.
    Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
    Biol Pharm Bull; 2010; 33(6):1073-6. PubMed ID: 20522982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
    Yao X; Yoshioka Y; Morishige T; Eto Y; Watanabe H; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
    Gene Ther; 2009 Dec; 16(12):1395-404. PubMed ID: 19641532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.
    Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Kawai Y; Mizuguchi H; Gao JQ; Mukai Y; Okada N; Nakagawa S
    Mol Ther; 2011 Sep; 19(9):1619-25. PubMed ID: 21673661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection.
    Yao X; Yoshioka Y; Eto Y; Morishige T; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
    Biochem Biophys Res Commun; 2007 Oct; 362(2):419-24. PubMed ID: 17707336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
    Okada Y; Okada N; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T
    Cancer Gene Ther; 2005 Jul; 12(7):608-16. PubMed ID: 15746944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer.
    Eto Y; Yoshioka Y; Ishida T; Yao X; Morishige T; Narimatsu S; Mizuguchi H; Mukai Y; Okada N; Kiwada H; Nakagawa S
    Biol Pharm Bull; 2010; 33(9):1540-4. PubMed ID: 20823571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy.
    Yao XL; Yoshioka Y; Ruan GX; Chen YZ; Mizuguchi H; Mukai Y; Okada N; Gao JQ; Nakagawa S
    Biomacromolecules; 2012 Aug; 13(8):2402-9. PubMed ID: 22746837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
    Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
    J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase.
    Mizuguchi H; Hayakawa T
    Cancer Gene Ther; 2002 Mar; 9(3):236-42. PubMed ID: 11896439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.
    Kia A; Przystal JM; Nianiaris N; Mazarakis ND; Mintz PJ; Hajitou A
    Mol Cancer Ther; 2012 Dec; 11(12):2566-77. PubMed ID: 23053496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer.
    Tong X; Engehausen DG; Freund CT; Agoulnik I; Oehler MK; Kim TE; Hasenburg A; Guo Z; Contant CF; Woo SL; Kieback DG
    Hybridoma; 1999 Feb; 18(1):93-7. PubMed ID: 10211795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of pegylated adenovirus vector for cancer gene therapy].
    Eto Y; Yoshioka Y; Asavatanabodee R; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
    Yakugaku Zasshi; 2008 Dec; 128(12):1733-42. PubMed ID: 19043292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy.
    Suzuki T; Sakurai F; Nakamura S; Kouyama E; Kawabata K; Kondoh M; Yagi K; Mizuguchi H
    Mol Ther; 2008 Oct; 16(10):1719-26. PubMed ID: 18665157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy.
    Lambright ES; Amin K; Wiewrodt R; Force SD; Lanuti M; Propert KJ; Litzky L; Kaiser LR; Albelda SM
    Gene Ther; 2001 Jun; 8(12):946-53. PubMed ID: 11426335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
    Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
    Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific transcriptional targeting of suicide gene therapy.
    Qiao J; Doubrovin M; Sauter BV; Huang Y; Guo ZS; Balatoni J; Akhurst T; Blasberg RG; Tjuvajev JG; Chen SH; Woo SL
    Gene Ther; 2002 Feb; 9(3):168-75. PubMed ID: 11859419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.
    Li HJ; Everts M; Yamamoto M; Curiel DT; Herschman HR
    Cancer Res; 2009 Jan; 69(2):554-64. PubMed ID: 19147569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.